Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

4%

Beneficial ownership of this reported class.

Shares

391,357 shares

Shares beneficially owned as disclosed.

Event date

22 Dec 2025

Date tied to the ownership event or amendment.

Accepted by SEC

29 Dec 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
INAB
Shares outstanding
9,783,925 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D/A
Accepted by SEC
29 Dec 2025, 16:00:52 UTC
Event date
22 Dec 2025
Prior SEC filing
08 May 2025
Source filing
View source filing
Filing notes and source

Key filing fact

BIOS Fund II, LP disclosed 4% ownership in IN8BIO, INC. Common Stock, par value $0.0001 per share (INAB) on 22 Dec 2025.

Key facts

  • BIOS Fund II, LP filed SCHEDULE 13D/A for IN8BIO, INC. Common Stock, par value $0.0001 per share (INAB).
  • Disclosed ownership: 4%.
  • Date of event: 22 Dec 2025.

Change

  • Disclosed shares changed by -8,728,716 since the prior disclosure.
  • Previous schedule filing date: 08 May 2025.
  • Current filing was accepted on 29 Dec 2025, 16:00.
  • Disclosed stake changed by -5.99 percentage points.
  • Changes between disclosures can reflect transactions, share-count changes or reporting changes; they do not establish a purchase or activist intent.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (19)

Names, ownership percentages, voting power, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power CIK
BIOS Fund II, LP 0.2% 19,147 0 19,147 0001714576
BIOS Fund II QP, LP 0.6% 62,554 0 62,554 0001716869
BIOS Fund II NT, LP 0.1% 8,373 0 8,373 0001728851
BIOS Incysus Co-Invest I, LP 0.3% 33,247 0 33,247 0001740029
BIOS Fund III, LP 0.2% 19,024 0 19,024 0001791917
BIOS Fund III QP, LP 1.3% 124,253 0 124,253 0001791916
BIOS Fund III NT, LP 0.2% 20,066 0 20,066 0001791910
Bios Clinical Opportunity Fund, LP 1.1% 104,693 0 104,693 0001988639
BP Directors, LP 0% 0 0 0 0001813311
Bios Equity Partners, LP 0% 0 0 0 0001813314
Bios Equity Partners II, LP 1.3% 123,321 0 123,321 0001813313
BIOS Equity Partners III, LP 1.7% 163,343 0 163,343 0001831976
Bios Equity COF, LP 1.1% 104,693 0 104,693 0002000747
Cavu Management, LP 2.9% 286,664 0 286,664 0001813270
BIOS Capital Management, LP 4% 391,357 0 391,357 0001813845
Cavu Advisors, LLC 2.9% 286,664 0 286,664 0001813310
BIOS Advisors GP, LLC 4% 391,357 0 391,357 0001813844
Kreis Leslie W. 2.9% 286,664 0 286,664 0001813316
Fletcher Aaron G.L. 4% 391,357 0 391,357 0001789490
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .